Dr. Ma discussed key findings that have been shared so far this year on the topic of evolving treatment strategies for ...

Recent ASCO 2025 findings reveal new insights into melanoma treatment, highlighting challenges and advancements in adjuvant ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer, in non ...

U.S. Market Leads with 74% Share in 2023 Valued at USD 2.71 Billion, Driven by Biotech Innovation, Favorable FDA Approvals, and Rising Chronic Disease Incidence.Austin, July 18, 2025 (GLOBE NEWSWIRE) ...

The response rate to Amtagvi was higher in patients who had received two or fewer therapies than in those with more heavily ...